Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.

Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.

Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.

Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.

Abstract: The common plant model offers the possibility to create a mechanism that allows an easier linking of plant items from an engineering aspect being independent of the system, such as MES, SCADA, DCS, ERP, the engineer is working with. The common plant model includes: a node type model aggregating different aspects for the modeling of a single physical plant item; a number of nodes; a library model with a project library and a global library; and a wiring chart model defining the interaction between interface members of different facets. Each facet has at least one interface member and the logical link among the interface members is a virtual wire defining a connection used to propagate and align facet parameters linked to a specific node. The wiring chart is usable by different users. The SCADA and DCS systems have access to the distinct modeling of their individual needs.

Abstract: A common plant model for the MES, SCADA and DCS systems of a production facility benefits from an integration architecture that enables a stringent and persistent modeling of the physical resources of a production facility. The common plant model for modeling of physical plant items within a manufacturing execution system having an engineering environment and a runtime environment, contains: a node type model aggregating different aspects for the modeling of a physical plant item containing public interface parameters and automation parameters; a number of nodes, each representing an instance of one distinct node type; a library model containing a project library and a global library, the libraries containing the node type model, a facet model, a rule model and a hierarchy model; a wiring chart model defining the interaction between interface members of different facets of a node; and a graph model representing physical and/or logical connections between the nodes.

Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.

Abstract: In an industrial automation system comprising a plurality of industrial control devices connected to an industrial communication network, control and/or supervision functions of the industrial automation system are provided by services implemented by computer-based objects in industrial control devices. A computer-based object is assigned a first qualifier enabling the computer-based object to be accessed and/or modified during configuration of the respective service and/or a second qualifier enabling the computer-based object to be accessed and/or modified during runtime of the respective service. Upon a request for access to a computer-based object by a service consumer, the service consumer's operational state is determined. Depending on a set first and/or second qualifier of a computer-based object and depending on a determined operational state of a service consumer, access to the computer-based object is granted to the service consumer.

Abstract: An automation system with a plurality of communicatively connected automation devices is disclosed. One of the connected automations devices serves as a domain controller and holds centrally in a memory data required for operation for the automation system and the automation devices. Hitherto frequently occurring multiple storage of such data is eliminated, the data is available at a central location for access by all the automation devices, and the domain controller, as a central data server, ensures consistency of the data administered and provided by it, which also permits access optimizations, such as e.g. device-, access- or structure-dependent temporary storage strategies.

Abstract: In an industrial automation system comprising a plurality of industrial control devices connected to an industrial communication network, control and/or supervision functions of the industrial automation system are provided by services implemented by computer-based objects in industrial control devices. A computer-based object is assigned a first qualifier enabling the computer-based object to be accessed and/or modified during configuration of the respective service and/or a second qualifier enabling the computer-based object to be accessed and/or modified during runtime of the respective service. Upon a request for access to a computer-based object by a service consumer, the service consumer's operational state is determined. Depending on a set first and/or second qualifier of a computer-based object and depending on a determined operational state of a service consumer, access to the computer-based object is granted to the service consumer.

Abstract: The invention relates to a solid pharmaceutical preparation containing one or more solid carriers and/or excipients and an active substance selected from among the Monoamine Neurotransmitter Re-uptake Inhibitors which have a 2,3-disubstituted tropane structure, the preparation thereof and use thereof for preparing a pharmaceutical composition for the treatment or prevention of central-nervous diseases or disorders.

Abstract: An automation system with a plurality of communicatively connected automation devices is disclosed. One of the connected automations devices serves as a domain controller and holds centrally in a memory data required for operation for the automation system and the automation devices. Hitherto frequently occurring multiple storage of such data is eliminated, the data is available at a central location for access by all the automation devices, and the domain controller, as a central data server, ensures consistency of the data administered and provided by it, which also permits access optimizations, such as e.g. device-, access- or structure-dependent temporary storage strategies.

Abstract: The invention relates to a mixing chamber for producing compressed air foam in fire extinguishing devices. The mixing chamber has a compressed air inlet, an extinguishing agent inlet and a compressed air foam outlet. The contour of the mixing chamber tapers towards the compressed air foam outlet. The invention also includes a fire extinguishing device. The fire extinguishing device includes an extinguishing agent container, a connecting device for connecting a source of compressed air to a mixing chamber of the kind described above.

Abstract: The inventions relates to a feed screw for eccentric screw pumps which, to avoid bridge formation of the medium and optimisation of the drive power, has a screw, which in the axial region, has perforations and webs.

Abstract: The here presented invention refers to a method and device for separating inorganic salts from loop-processed toilet waste water as well as its de-colouring. Additionally, a treatment method without a biological step is presented, whereas here as well the toilet waste water is loop-processed reasoned by water savings and amounts reduction preferably for mobile units. The here presented invention refers to a method and device refer also to the extraction of nutrient salts from toilet and/or urinal waste waters, whereas the method comprises the steps urea cleavage, removal of ammonium, and reuse of the toilet flushing water for toilet flushing and these steps are executed preferably in separated devices.

Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.

Abstract: The invention relates to a method for the treatment of female sexual disorders comprising administration of a therapeutically effective amount of a compound of general formula 1 wherein the groups R, L and X may have the meanings specified in the description and claims.

Abstract: The invention relates to a new pharmaceutical formulation, containing an LTB4 antagonist of formula I wherein A, R1, R2, R3 and R4 are defined as in claim 1, the pharmacologically acceptable acid addition salt, glycoside, O-sulphate or glucuronide thereof as active substance as well as optionally at least one pharmacologically acceptable excipient and/or carrier, the active substance being present as a solid solution or solid dispersion in a polymer matrix. The invention also relates to the preparation thereof and their use as pharmaceutical compositions as well as the solid solutions and dispersions per se.

Abstract: The invention relates to a solid pharmaceutical preparation containing one or more solid carriers and/or excipients and an active substance selected from among the Monoamine Neurotransmitter Re-uptake Inhibitors which have a 2,3-disubstituted tropane structure, the preparation thereof and use thereof for preparing a pharmaceutical composition for the treatment or prevention of central-nervous diseases or disorders.

Abstract: The invention relates to a new formulation for oral administration of active substances with pH-dependent solubility characteristics and the pharmacologically acceptable salts thereof, which improves the bioavailability of the active substance.